The composition and activation status of the cellular milieu contained within the tumour microenvironment (TME) is becoming increasingly recognized as a driving factor for immunotherapy response. Here, we employed multiplex immunohistochemistry (mIHC), and digital spatial profiling (DSP) to capture the targeted immune proteome and transcriptome of tumour and TME compartments from an immune checkpoint inhibitor (ICI)-treated (n = 41) non-small cell lung cancer (NSCLC) patient cohort. We demonstrate by mIHC that the interaction of CD68+ macrophages with PD1+, FoxP3+ cells is enriched in ICI refractory tumours (p = 0.012). Patients responsive to ICI therapy expressed higher levels of IL2 receptor alpha (CD25, p = 0.028) within their tumour com...
The impacts of the tumor microenvironment (TME) on tumor evolvability remain unclear. A challenge fo...
Most patients with advanced non-small-cell lung cancer (NSCLC) fail to derive significant benefit fr...
BackgroundImmunotherapy has gradually become an important therapy option for lung cancer patients.Me...
Introduction: Immunotherapies, such as immune checkpoint inhibitors (ICI) have shown durable benefit...
Background: Profiling the tumour microenvironment (TME) has been informative in understanding the un...
Introduction: Immune cells in the tumour microenvironment are associated with prognosis and response...
Profiling the tumour microenvironment (TME) has been informative in understanding the underlying tum...
Background: Immune checkpoint inhibitors (ICI) have shown durable and long-term benefits in a subset...
Non-small cell lung cancer (NSCLC) is one of the most common cancers globally and has a 5-year survi...
Mucosal head and neck squamous cell carcinoma (HNSCC) are the seventh most common cancer, with appro...
As targeted molecular therapies and immuno-oncology have become pivotal in the management of patient...
Non-small cell lung cancer (NSCLC) is one of the most common types of cancer in the world and has a ...
The use of immune checkpoint inhibitors (ICIs) continues to transform the therapeutic landscape of n...
Cancer is a leading cause of premature death and lung cancer is the deadliest cancer type, with non-...
Abstract Background Permanence of front-line manageme...
The impacts of the tumor microenvironment (TME) on tumor evolvability remain unclear. A challenge fo...
Most patients with advanced non-small-cell lung cancer (NSCLC) fail to derive significant benefit fr...
BackgroundImmunotherapy has gradually become an important therapy option for lung cancer patients.Me...
Introduction: Immunotherapies, such as immune checkpoint inhibitors (ICI) have shown durable benefit...
Background: Profiling the tumour microenvironment (TME) has been informative in understanding the un...
Introduction: Immune cells in the tumour microenvironment are associated with prognosis and response...
Profiling the tumour microenvironment (TME) has been informative in understanding the underlying tum...
Background: Immune checkpoint inhibitors (ICI) have shown durable and long-term benefits in a subset...
Non-small cell lung cancer (NSCLC) is one of the most common cancers globally and has a 5-year survi...
Mucosal head and neck squamous cell carcinoma (HNSCC) are the seventh most common cancer, with appro...
As targeted molecular therapies and immuno-oncology have become pivotal in the management of patient...
Non-small cell lung cancer (NSCLC) is one of the most common types of cancer in the world and has a ...
The use of immune checkpoint inhibitors (ICIs) continues to transform the therapeutic landscape of n...
Cancer is a leading cause of premature death and lung cancer is the deadliest cancer type, with non-...
Abstract Background Permanence of front-line manageme...
The impacts of the tumor microenvironment (TME) on tumor evolvability remain unclear. A challenge fo...
Most patients with advanced non-small-cell lung cancer (NSCLC) fail to derive significant benefit fr...
BackgroundImmunotherapy has gradually become an important therapy option for lung cancer patients.Me...